About qiagen nv - QGEN
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Its sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
QGEN At a Glance
QIAGEN NV
Hulsterweg 82
Venlo, Limburg 5912 PL
| Phone | 31-77-355-66-00 | Revenue | 2.09B | |
| Industry | Medical Specialties | Net Income | 424.88M | |
| Sector | Health Technology | 2025 Sales Growth | 5.651% | |
| Fiscal Year-end | 12 / 2026 | Employees | 5,654 | |
| View SEC Filings |
QGEN Valuation
| P/E Current | 19.885 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 23.167 |
| Price to Sales Ratio | 4.71 |
| Price to Book Ratio | 2.60 |
| Price to Cash Flow Ratio | 15.04 |
| Enterprise Value to EBITDA | 14.784 |
| Enterprise Value to Sales | 5.051 |
| Total Debt to Enterprise Value | 0.172 |
QGEN Efficiency
| Revenue/Employee | 369,649.629 |
| Income Per Employee | 75,146.799 |
| Receivables Turnover | 4.019 |
| Total Asset Turnover | 0.349 |
QGEN Liquidity
| Current Ratio | 3.896 |
| Quick Ratio | 3.306 |
| Cash Ratio | 2.146 |
QGEN Profitability
| Gross Margin | 61.794 |
| Operating Margin | 24.895 |
| Pretax Margin | 23.458 |
| Net Margin | 20.329 |
| Return on Assets | 7.099 |
| Return on Equity | 11.568 |
| Return on Total Capital | 7.60 |
| Return on Invested Capital | 8.044 |
QGEN Capital Structure
| Total Debt to Total Equity | 47.97 |
| Total Debt to Total Capital | 32.419 |
| Total Debt to Total Assets | 28.854 |
| Long-Term Debt to Equity | 47.207 |
| Long-Term Debt to Total Capital | 31.903 |